Athersys (ATHX) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock ATHX vs. SPRB, AFMD, GRAY, PTN, VCNX, GRTX, ONCT, BPTH, OGEN, and ASLNShould you be buying Athersys stock or one of its competitors? The main competitors of Athersys include Spruce Biosciences (SPRB), Affimed (AFMD), Graybug Vision (GRAY), Palatin Technologies (PTN), Vaccinex (VCNX), Galera Therapeutics (GRTX), Oncternal Therapeutics (ONCT), Bio-Path (BPTH), Oragenics (OGEN), and ASLAN Pharmaceuticals (ASLN). Athersys vs. Its Competitors Spruce Biosciences Affimed Graybug Vision Palatin Technologies Vaccinex Galera Therapeutics Oncternal Therapeutics Bio-Path Oragenics ASLAN Pharmaceuticals Athersys (NASDAQ:ATHX) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk. Which has more volatility and risk, ATHX or SPRB? Athersys has a beta of -0.9, meaning that its share price is 190% less volatile than the S&P 500. Comparatively, Spruce Biosciences has a beta of 2.4, meaning that its share price is 140% more volatile than the S&P 500. Is ATHX or SPRB more profitable? Athersys has a net margin of 0.00% compared to Spruce Biosciences' net margin of -555.23%. Athersys' return on equity of 0.00% beat Spruce Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets AthersysN/A N/A -223.03% Spruce Biosciences -555.23%-62.10%-47.49% Which has better earnings and valuation, ATHX or SPRB? Spruce Biosciences has higher revenue and earnings than Athersys. Spruce Biosciences is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAthersys$146K0.00-$72.53M-$2.03N/ASpruce Biosciences$4.91M0.92-$47.92M-$1.32-0.08 Does the media prefer ATHX or SPRB? In the previous week, Athersys' average media sentiment score of 0.75 beat Spruce Biosciences' score of 0.00 indicating that Athersys is being referred to more favorably in the media. Company Overall Sentiment Athersys Positive Spruce Biosciences Neutral Do analysts recommend ATHX or SPRB? Spruce Biosciences has a consensus target price of $1.75, suggesting a potential upside of 1,535.51%. Given Spruce Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Spruce Biosciences is more favorable than Athersys.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Athersys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Spruce Biosciences 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do institutionals and insiders hold more shares of ATHX or SPRB? 19.4% of Athersys shares are held by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are held by institutional investors. 0.0% of Athersys shares are held by company insiders. Comparatively, 6.9% of Spruce Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummarySpruce Biosciences beats Athersys on 9 of the 13 factors compared between the two stocks. Get Athersys News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATHX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATHX vs. The Competition Export to ExcelMetricAthersysPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$833K$760.73M$5.52B$9.35BDividend YieldN/A4.84%4.25%4.09%P/E Ratio0.001.4027.9519.83Price / SalesN/A25.53438.79106.18Price / CashN/A19.5635.5357.53Price / BookN/A6.708.255.72Net Income-$72.53M-$4.32M$3.23B$257.51M Athersys Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATHXAthersysN/AN/AN/AN/A$833K$146K0.0024SPRBSpruce Biosciences2.0525 of 5 stars$0.07-3.3%$1.75+2,400.0%-82.9%$2.96M$4.91M-0.0720AFMDAffimed2.8392 of 5 stars$0.18-34.9%$3.62+1,895.9%-96.7%$2.92M$877K0.00200Gap DownHigh Trading VolumeGRAYGraybug VisionN/A$1.61+1.9%N/A-57.4%$2.53MN/A-0.9327High Trading VolumePTNPalatin TechnologiesN/A$0.09-44.6%N/AN/A$2.45M$350K-0.0630Gap DownHigh Trading VolumeVCNXVaccinex0.8191 of 5 stars$0.80+14.4%N/A-85.4%$2.08M$388K-0.0240GRTXGalera Therapeutics0.235 of 5 stars$0.03-11.6%N/A-77.9%$1.96MN/A-0.0730Gap DownONCTOncternal TherapeuticsN/A$0.53flat$10.00+1,799.0%N/A$1.56M$790K-0.0530BPTHBio-Path0.8191 of 5 stars$0.16-6.0%N/A-91.8%$1.33MN/A0.0010Gap UpOGENOragenics0.0666 of 5 stars$1.54+0.7%N/A-95.8%$1.27MN/A-0.225News CoverageHigh Trading VolumeASLNASLAN PharmaceuticalsN/A$0.60flatN/AN/A$1.23M$12M-0.0330 Related Companies and Tools Related Companies Spruce Biosciences Competitors Affimed Competitors Graybug Vision Competitors Palatin Technologies Competitors Vaccinex Competitors Galera Therapeutics Competitors Oncternal Therapeutics Competitors Bio-Path Competitors Oragenics Competitors ASLAN Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATHX) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Athersys, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Athersys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATHX Stock Alerts